Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Volunteers

Next Previous
Trial Profile

A First-in-human, Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EA 1080 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man
  • Sponsors EA Pharma

Most Recent Events

  • 21 Feb 2025 According to Ensho Therapeutics media release, the company presented the additional supportive data for NSHO-101 at the 20th congress of the European Crohn's and Colitis Organisation (ECCO 2025) meeting being held in Berlin, Germany.
  • 14 Feb 2025 According to Ensho Therapeutics media release, additional analyses from this trial will be presented at the 20th congress of the European Crohn's and Colitis Organisation (ECCO 2025) being held February 19 to 22, 2025, in Berlin, Germany, in a Guided Poster Session on Friday, February 21, 12:40-13:40 CET.
  • 27 Jun 2024 Results presented in an Ensho Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top